Home' Australian Pharmacist : Australian Pharmacist August 2013 Contents 80
Australian Pharmacist August 2013 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Australian Pharmacist is a professional journal providing community pharmacists with a
range of peer reviewed articles that are interesting and evidence-based to ensure credibility
and accuracy. The journal has an extremely strong CPD program followed by nearly 10,000
pharmacists and a typical monthly article receives more than 2950 assessments, with highs
Read in greater detail and more regularly than any other pharmacy title – such constant
behaviour means you can count on our readers to open any issue and be seen!
» Read by 65% of community pharmacists
» The most valued and used for clinical information, continuing education, prescription
medicines, scheduled medicines, professional services and patient counselling
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2012
Adding the best read pages in pharmacy media to your campaign will result in greater
impact, leading to greater recognition – package with the Australian Pharmacist
eBulletin to gain further recognition with 12,000 community pharmacists and high
open rates of 30%.
Ph: 02 9988 4689
Ph: 02 9547 3001
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
• Prevention of venous
thromboembolism (VTE) in adult
patients who have undergone major
orthopaedic surgery of the lower
limbs (elective total hip replacement,
treatment for up to five weeks; elective
total knee replacement, treatment for
up to two weeks).
Known as a direct Factor Xa Inhibitor,2
rivaroxaban works by directly targeting
the clotting Factor Xa which is essential
for thrombin production, thereby
reducing the risk of thrombus formation.2
It does not require INR testing to check
dosing, adjustments to dosages (except
in moderate renal impairment) or dietary
restrictions.1,3 The 15 mg and 20 mg
tablets should be taken with food.
The efficacy and safety profile
of rivaroxaban in non-valvular
atrial fibrillation is supported by a
comprehensive clinical program involving
over 14,200 patients which forms part
of the larger global Xarelto clinical
development program.1,4–7 Additionally,
the efficacy and safety profile of the
therapy for treatment of acute pulmonary
embolism (PE) and prevention of
recurrent venous thromboembolism (VTE)
is supported by a comprehensive clinical
program involving over 4,800 patients.
1. Xarelto Product Information. Jun 2013.
2. Turpie AG. Oral, direct factor Xa inhibitors in development for
the prevention and treatment of thromboembolic diseases.
Arterioscler. Throm. Vasc. Biol. 2007;27,(6)1238-47 .
3. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban
for symptomatic venous thromboembolism N Eng J Med.
4. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group.
Rivaroxaban versus enoxaparin for thromboprophylaxis after
hip arthroplasty. N Engl J Med. 2008;358(26):2765-75.
5. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators.
Extended duration rivaroxaban versus short-term enoxaparin
for the prevention of venous thromboembolism after total
hip arthroplasty: a double-blind, randomised controlled trial.
Lancet. 2008;372(9632):31-39 .
6. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators.
Rivaroxaban versus enoxaparin for thromboprophylaxis after
total knee arthroplasty. N Engl J Med. 2008;358(26):2776-86 .
7. Turpie AGG, Lassen MR, Davidson BL, et al; RECORD4
Investigators. Rivaroxaban versus enoxaparin for
thromboprophylaxis after total knee arthroplasty (RECORD4): a
randomised trial. Lancet. 2009;373(9676):1673-80.
Bear Grylls partners with
Nature’s Own has launched a partnership
with adventurer, survival expert, TV host
and author Bear Grylls. The partnership has
Bear appearing in television, print, outdoor
and in-pharmacy advertising where he will
take on a new challenge – can he replicate
Nature’s Own products with nature alone?
Speaking about the partnership Bear said, ‘I
am super excited to be part of the Nature’s
Own and Sanofi team, as I’m a big believer
in great attitude and great health. Vitamins
are a key part of keeping healthy; as they
can help us make the most of our health
Luke Fitzgerald, Director of Sanofi Consumer
Healthcare the makers of Nature’s Own
said: ‘At Nature’s Own we take the best of
nature and optimise it through science to
deliver evidence based products that help
Australians maintain and improve their
health. Bear Grylls is an expert in his field
and recognises the importance of vitamins,
minerals and supplements to support his
and his families’ lifestyle. He chose to partner
with us knowing he would be representing
a brand that’s underpinned by knowledge
Luke said the partnership with Bear
Grylls was another step in the ongoing
transformation of Nature’s Own,’ he said.
‘We want our consumers to know we
are serious about providing them with
evidence-based products, most of which are
researched, developed and manufactured
locally at our world class facility in Brisbane.
That’s why we are rolling out new look
Nature’s Own packaging and new shopper
solutions units. It’s also why we have
partnered with Bear Grylls – to helping
our customers understand the quality
and evidence that underpins the Nature’s
Links Archive Australian Pharmacist July 2013 Australian Pharmacist Sept 2013 Navigation Previous Page Next Page